CROI

CROI
February 22-25, 2026
Denver, Colorado

Conference on Retroviruses and Opportunistic Infections .

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (16)

    Nonclinical Pharmacology of GS -3242, a Novel Long -Acting Injectable INSTI in Clinical Development

    • Author(s): Hansen, D
    • gs-3242
    • HIV / AIDS

    Switch to BIC+LEN in VS PWH on Complex Regimens: Week 96 Outcomes

    • Author(s): Hedgcock, M
    • bic/len
    • HIV / AIDS

    Expected Impact of Twice-Yearly Lenacapavir on PrEP Coverage Disparities and HIV Incidence in the US

    • Author(s): Moore, M
    • lenacapavir
    • HIV / AIDS

    Nonclinical Pharmacokinetics of a Novel INSTI GS-3242 supports a Human Long -Acting Injectable

    • Author(s): Subramanian, M
    • gs-3242
    • HIV / AIDS

    Real-World Medication Use and Potential Interactions with Lenacapavir for HIV PrEP

    • Author(s): Tao, L
    • lenacapavir
    • HIV / AIDS

    Twice -Yearly Lenacapavir, Teropavimab, and Zinlirvimab for HIV -1: Week 52 Resistance Analyses

    • Author(s): VanderVeen, L
    • teropavimab
    • lenacapavir
    • HIV / AIDS

    Genetic characterization of HIV -1 subtype C env and gag sequences derived from transmitted/founder and rebound viruses from participants in an analytical treatment interruption clinical trial

    • Author(s): Gumede, N
    • other
    • HIV / AIDS

    Once -Weekly Islatravir Plus Lenacapavir Maintains HIV -1 Suppression Through 96 Weeks: Phase 2 Study

    • Author(s): Colson, A
    • lenacapavir plus islatravir
    • HIV / AIDS

    Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV -1 at 96 Weeks

    • Author(s): Bekerman, E
    • lenacapavir plus islatravir
    • HIV / AIDS

    Long -term Effectiveness of Lenacapavir in Heavily Treatment -Experienced People with HIV-1 in the US

    • Author(s): Ogbuagu, O
    • len for hte pwh
    • HIV / AIDS

    Patient -Reported Outcomes after 52 Weeks of Twice -Yearly Lenacapavir, Teropavimab, and Zinlirvimab

    • Author(s): Gaur, A
    • lenacapavir
    • teropavimab
    • HIV / AIDS

    Once-Yearly Lenacapavir for PrEP: Model-Informed Dose Determination and Phase 3 Trial Design

    • Author(s): Johnston, C
    • lenacapavir
    • HIV / AIDS

    Phase 3 Efficacy and Safety of Switch from B/F/TAF to Single -Tablet BIC/LEN in ARTISTRY -2

    • Author(s): Meissner, E
    • bic/len
    • HIV / AIDS

    Efficacy and Safety of B/F/TAF in Children and Infants Aged ≥1 Month, Weighing 3 to <25 kg: Week 24

    • Author(s): Natukunda, E
    • b/f/taf
    • HIV / AIDS

    BNAb sensitivity does not fully explain post-treatment control in early HIV -treated women during ATI

    • Author(s): Selzer, L
    • other
    • HIV / AIDS

    Safety, PK, and Pharmacodynamics of Amtabafusp, a Bispecific T -cell Engager, in People with HIV

    • Author(s): Workowski, K
    • amtabafusp
    • HIV / AIDS